Zobrazeno 1 - 10
of 73
pro vyhledávání: '"Marcela V Maus"'
Publikováno v:
Annual Review of Cancer Biology. 7:23-42
Chimeric antigen receptor (CAR) T cell therapy has emerged as a new opportunity for cancer treatment; however, resistance can occur due to intrinsic (T cells), extrinsic (tumors), or acquired (tumors) factors. In many cases, the knowledge of these me
Autor:
Kimberly R. Hagel, Rand Arafeh, Sydney Gang, Taylor E. Arnoff, Rebecca C. Larson, John G. Doench, Nathan D. Mathewson, Kai W. Wucherpfennig, Marcela V. Maus, William C. Hahn
Publikováno v:
Cancer Research. 83:613-625
Chimeric antigen receptor (CAR) T-cell therapy can lead to dramatic clinical responses in B-cell malignancies. However, early clinical trials with CAR T-cell therapy in non–B-cell malignancies have been disappointing to date, suggesting that tumor-
Autor:
Andrea Schmidts, Ambike A Srivastava, Rishab Ramapriyan, Stefanie R Bailey, Amanda A Bouffard, Daniel P Cahill, Bob S Carter, William T Curry, Gavin P Dunn, Matthew J Frigault, Elizabeth R Gerstner, Jack Y Ghannam, Michael C Kann, Rebecca C Larson, Mark B Leick, Brian V Nahed, Leland G Richardson, Irene Scarfò, Jing Sun, Hiroaki Wakimoto, Marcela V Maus, Bryan D Choi
Publikováno v:
Neuro-Oncology Advances. 5
Background Chimeric antigen receptor (CAR) T cells have achieved remarkable responses in patients with hematological malignancies; however, the potential of this therapeutic platform for solid tumors like glioblastoma (GBM) has been limited, due in l
Autor:
Joan How, Kathleen M. E. Gallagher, Yiwen Liu, Katelin Katsis, Eva L. Elder, Rebecca C. Larson, Mark B. Leick, Donna Neuberg, Marcela V. Maus, Gabriela S. Hobbs
Publikováno v:
Leukemia. 36:1176-1179
Autor:
Mark B. Leick, Marcela V. Maus
Publikováno v:
Nature Reviews Clinical Oncology. 20:285-286
Autor:
Nikhil C. Munshi, Christopher J. Gibson, Caron A. Jacobson, Peter Miller, Max Jan, Mark B. Leick, Geoffrey Fell, Benjamin L. Ebert, Marcela V. Maus, Elliott J. Brea, Yu-Tzu Tai, Satyen H. Gohil, Donna Neuberg, Catherine J. Wu, Adam S. Sperling
Publikováno v:
Blood Adv
Chimeric antigen receptor (CAR) T-cells have emerged as an efficacious modality in patients with non-Hodgkin lymphoma (NHL) and multiple myeloma (MM). Clonal hematopoiesis of indeterminate potential (CHIP), a state in which mutations in hematopoietic
Autor:
Felix Korell, Michael Olson, Diego Salas-Benito, Mark B. Leick, Rebecca C. Larson, Harrison Silva, Alessandro Gasparetto, Trisha R. Berger, Amanda Bouffard, Michael C. Kann, Markus Mergen, Tamina Kienka, Marc Wehrli, Stefanie R. Bailey, Anthony Letai, Marcela V. Maus
Publikováno v:
Cancer Research. 83:4098-4098
Background: Chimeric antigen receptor (CAR) T cells have become a well-established treatment option for patients, with six products approved for different hematologic diseases and new approvals allowing for their therapeutic use as early as second li
Publikováno v:
Annual Review of Medicine. 72:365-382
Adoptive transfer of T cells modified with chimeric antigen receptors (CAR-T cells) has changed the therapeutic landscape of hematological malignancies, particularly for acute lymphoblastic leukemia and large B cell lymphoma, where two different CAR-
Autor:
Reuben Benjamin, Charlotte Graham, Deborah Yallop, Agnieszka Jozwik, Oana C Mirci-Danicar, Giovanna Lucchini, Danielle Pinner, Nitin Jain, Hagop Kantarjian, Nicolas Boissel, Marcela V Maus, Matthew J Frigault, André Baruchel, Mohamad Mohty, Athos Gianella-Borradori, Florence Binlich, Svetlana Balandraud, Fabien Vitry, Elisabeth Thomas, Anne Philippe, Sylvain Fouliard, Sandra Dupouy, Ibtissam Marchiq, Maria Almena-Carrasco, Nicolas Ferry, Sylvain Arnould, Cyril Konto, Paul Veys, Waseem Qasim, Antonio Pagliuca, Ghulam Mufti, Piers Patten, Shireen Kassam, Stephen Devereux, Majid Kazmi, Kirsty Cuthill, Victoria Potter, Andrea Kuhnl, Victoria Metaxa, Laarni Bonganay, Orla Stewart, Rose Ellard, Lorraine Catt, Jen Lewis, Farzin Farzaneh, Jackie Chappell, Alice Mason, Vicky Chu, Alan Dunlop, Adeel Saleem, Gary Cheung, Helena Munro, Elka Giemza, Oana Ciocarlie, Jan Chu, Persis Amrolia, Kanchan Rao, Robert Chiesa, Juliana Silva, Annette Hill, Maria Finch, Lindsey Young, Harvinder Hara, Sujith Samarasinghe, Anupama Rao, Ajay Vora, Kimberley Gilmour, Christine Rivat, Clare Murphy, Gulrukh Ahsan, Rasha Said Shamsah, Jesmina James, Sarah Inglott, Gary Wright, Stuart Adams, Natalia Izotova, Marina Konopleva, William Wierda, Elias Jabbour, Partow Kebrieai, Emily Jones, Kara McGee, Marcela Maus, Matthew Frigault, Jami Brown, Vesselina Toncheva, Keagan Casey, Hanno Hock, Meaghan A McKeown, Richard Mathews, Thomas Spitzer, Emmanuel Raffoux, Etienne Lengliné, Raphael Itzykson, Florence Rabian, Jérôme Larghero, Isabelle Madelaine, Elie Azoulay, Emmanuelle Clappier, Sophie Caillat-Zucman, Martine Meunier, Karine Celli-Lebras, Marie-Thérèse Tremorin, Karima Yakouben, Françoise Mechinaud-Heloury, Audrey Grain, Aurélia Alimi, Julie Roupret, Delphine Chaillou, Hélène Cavé, Aurelie Caye-Eude, Odile Fenneteau, Elodie Lainey, Jerome Naudin, Eolia Brissot, Remy Dulery, Florent Malard, Clémence Mediavilla, Agnès Bonnin, Anne Vekhoff, Tounes Ledraa, Anne Daguenel-Nguyen
Publikováno v:
The Lancet. 396:1885-1894
Summary Background Genome-edited donor-derived allogeneic anti-CD19 chimeric antigen receptor (CAR) T cells offer a novel form of CAR-T-cell product that is available for immediate clinical use, thereby broadening access and applicability. UCART19 is
Autor:
Scott J. Rodig, Mikel Lipschitz, Elizabeth Budde, Jeremy S. Abramson, Jonathon B. Cohen, Utkarsh Acharya, Michael Rogalski, Jerome Ritz, Yusuke Kamihara, Pei Hsuan Chen, Matthew J. Frigault, Stephen D. Smith, Bradley D. Hunter, Marcela V. Maus, Sarah Nikiforow, Joseph E. Maakaron, Philippe Armand, Matthew Mei, Alex F. Herrera, Robert A. Redd, Justin Kline, Ajay K. Gopal, Yi-Bin Chen, Caron A. Jacobson, Samantha Jaglowski, Kyle Wright, David G. Maloney
Publikováno v:
Journal of Clinical Oncology. 38:3095-3106
PURPOSE Axicabtagene ciloleucel (axi-cel) was approved by the Food and Drug Administration for relapsed aggressive B-cell non-Hodgkin lymphoma in part on the basis of durable remission rates of approximately 40% in a clinical trial population. Whethe